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ABSTRACT
The purpose of this study was to investigate the role
of metabotropic glutamate receptors (mGluR) in the ontogeny
of amphetamine-induced behavioral sensitization. 11-day-
old rat pups were given 5 daily bilateral infusions of the
metabotropic glutamate receptor antagonist, (RS)-methyl-4-
carboxyphenylglycine (MCPG) (0.0, 2.5, or 25.0 nM) followed
by a systemic injection of amphetamine (0.0 or 2.0 mg/kg)
and locomotor activity was measured. Following a 48 hr
abstinence period, rats were given a challenge injection of
amphetamine (0.0 or 0.5 mg/kg) and locomotor activity was
again measured. It was hypothesized that rats receiving
amphetamine pretreatment and an amphetamine challenge would
exhibit a significant increase in activity, indicating
short-term behavioral sensitization. In contrast with
studies on adult rats, behavioral sensitization in rat pups
was not expected to be attenuated by the actions of MCPG on
the mGluR system. As predicted, repeated amphetamine
administration during the pretreatment phase produced
progressively enhanced locomotor activity, indicating the
development of behavioral sensitization. Pretreatment with
the low dose of MCPG (2.5 nM) significantly attenuated
amphetamine-induced locomotor activity while the high dose
iii
of MCPG (25.0 nM) did not significantly affect locomotion.
Interestingly, pretreatment with 25.0 nM MCPG significantly
increased the locomotor response to a challenge injection
of amphetamine in all rats, regardless of amphetamine or
saline exposure during pretreatment. The effect of MCPG on 
locomotor activity ^appears to be independent from the 
effects of amphetamine-induced locomotor activity and MCPG
pretreatment failed to consistently block the expression of
behavioral sensitization in rats pretreated with
amphetamine and challenged with amphetamine.
Interpretations and possible molecular mechanisms
responsible for these results will be explored in the
discussion section. In summary, this study demonstrates
that contrary to previous studies on adult rats, the mGluR
system does not appear to consistently mediate the
development of amphetamine-induced sensitization in
neonatal rats.
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CHAPTER ONE
INTRODUCTION
Overview
Abuse of the psychostimulant amphetamine and its
analogs, methamphetamine and 3,4-methylenedioxy (MDMA)
"Ecstasy", is a major problem of modern society and affects
all races and socioeconomic classes. According to the 2000
National Household Survey on Drug Abuse, an estimated 8.8
million people (4.0% of the population) have tried
methamphetamine at some time in their lives (National
Institute on Drug Abuse [NIDA], 2002). Moreover, there
has been an upward trend in the use of. psychostimulants,
with treatment admissions for the abuse of methamphetamine
increasing 294% between 1992 and 1996 (Substance Abuse and
Mental Health Services, 1999).
The cause of the recent upsurge of amphetamine abuse
is unknown but it may be a consequence of amphetamines'
many uses and increased availability. Amphetamines have a
number of physiological properties that make them common
drugs of abuse. For example, amphetamines are abused
recreationally for their ability to elevate mood and
increase overall feelings of well-being (Hegadoren, Baker &
1
Bourin, 1999) . In addition, amphetamines are often misused
and abused in occupational settings by truck drivers,
physicians, students, construction workers, and athletes
for their ability to increase stamina, promote alertness
and relieve stress (Nencini & Ahmed, 1989; Singh & Jindal,
1980). The availability and low cost of illicit
methamphetamine has also increased abuse rates. In
contrast to cocaine, which must be imported,
methamphetamine can be manufactured very cheaply from
ingredients found in over-the-counter cold medications.
Thus, as law enforcement has seen some success in
preventing the inflow of cocaine, the production and
distribution of methamphetamine has risen.
In humans, chronic misuse of amphetamines can lead to
long-lasting impairments in brain function and behavior
(Robinson & Becker, 1986) . Particularly, repeated
amphetamine administration can produce paranoia, delusions,
hallucinations, and violent behavior (Cretzmeyer, Sarrazin,
Huber, Block, & Hall, 2003; Robinson & Becker, 1986; Satel,
Southwick, & Gawin, 1991). The cause of these behavioral
impairments are unknown, however, positron emission
tomography (PET) studies have found that individuals who
2
are methamphetamine abusers have a lower level of dopamine
D2 receptors (Volkow et al., 2001).
More conclusive evidence for the negative impact of
amphetamine exposure on brain functioning and behavior has
been yielded by studies in adult rodents. These studies
have found that repeated amphetamine exposure induces
central nervous system (CNS) cell death and produces a
long-term change in behavior, called behavioral
sensitization (Cretzmeyer et al., 2003; Robinson &
Berridge, 2001; Volkow, Fowler, Wang, & Goldstein, 2002).
This change in behavior is characterized by a progressive
and enduring enhancement of the drug-induced behavioral
effects of amphetamine (Kalivas & Stewart, 1991; Robinson &
Berridge, 2001; Sorg & Newlin, 2002). Behavioral
sensitization can be observed after as little as one drug
exposure and can still be detected for at least one year
after the last drug exposure (Kalivas & Stewart, 1991;
Robinson & Becker, 1986) . Much of the interest generated
about behavioral sensitization stems from its utility as an
animal analog of human psychosis (Kalivas & Stewart, 1991)
and as a model of human drug addiction (Davidson, Gow, Lee,
& Ellinwood, 2001; Self & Nestler, 1998).
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Given that amphetamine abuse can cause long-term
changes in brain functioning, it is alarming that the
recent increase in amphetamine abuse includes large numbers
of teenagers and young adults (Hegadoren et al., 1999). In
2000, 4.4% of high school seniors reported using
methamphetamine at least once in their lifetime and high
school students reported having been exposed to
methamphetamine by as early as the 8th-grade (NIDA, 2002). 
The use of MDMA among younger populations has increased
dramatically both in the United States (US) and
internationally. A 2003 survey of 44,000 US high school 
students in the 12th grade found that 8.3% reported MDMA use 
(Johnston, O'Malley & Bachman, 2003). A review of studies
conducted in other countries, including Australia and
various European countries, found that 1% to 13% of people
surveyed reported using MDMA in their lifetime (Parrott,
2001).
Moreover, a large number of young children are also
exposed to amphetamine as a treatment for attention-
deficit-hyperactivity-disorder (ADHD). It is estimated
that 7-16% of all school-aged children in the US suffer
from this disorder and the majority of these children are
treated with amphetamine or the amphetamine-derivative,
4
methylphenidate (Solanto, 2002; Teo, Stirling, Thomas,
Hobermen, Christian, & Khetani, 2002; Yang, Swann & Dafny,
2003) .
Proposal
At present, there have been very few studies examining
the effects of chronic amphetamine exposure in human
children or teenagers. However, animal studies have
revealed that the developing and the adult brain respond
differently to repeated psychostimulant exposure,
particularly in the expression of behavioral sensitization
(McDougall, Duke, Bolanos & Crawford, 1994; Tirelli &
Ferrara, 1997; Tirelli, Laviola & Adriani, 2003; Wood,
Tirelli, Snyder, Heyser, LaRocca & Spear, 1998). Research
now shows that no single neuronal system is entirely
responsible for the development of behavioral sensitization
(Pierce & Kalivas, 1997; Wolf, 1998). The dopamine system
has been identified as being primarily responsible for the
rewarding effects of amphetamine (Genova et al., 1997;
Pierce & Kalivas, 1997), in addition, an increasing amount
of evidence is pointing towards the regulatory role of the
metabotropic glutamate receptor system on the functions of
5
the dopamine system (Ohno & Watanabe, 1995; Saccan et al.,
1992) .
Thus, the following study examines the effects of
repeated amphetamine treatment during early development
using the behavioral sensitization paradigm. Specifically,
this thesis will assess the role of the metabotropic
glutamate receptor system in the development of behavioral
sensitization in the young rat. Identifying the response
of the developing brain to psychostimulant exposure will
help develop a greater understanding of the
neuropharmacological circuitry that is involved in the
process of behavioral sensitization and drug addiction.
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CHAPTER 2
DOPAMINE SYSTEM
Dopamine Synthesis and Transmission
Dopamine belongs to a small group of monoamine
neurotransmitters called the catecholamines. Dopamine
synthesis involves the conversion of the amino acid,
tyrosine, to L-dihydroxyphenylalanine (L-Dopa) by the
enzyme, tyrosine hydroxylase (TH) (Cooper, Bloom & Roth,
1996). L-Dopa is then converted to dopamine by the enzyme,
dopa decarboxylase (Cooper et al., 1996). The release of
dopamine from the nerve terminal into the synaptic cleft is
calcium-dependent and results from nerve impulse
stimulation in the form of an action potential (Chesselet,
1994). The effects of the released dopamine in the
synaptic cleft are mediated by activation of dopamine
receptors (Meador-Woodruff, 1994). Dopamine receptors are
found both presynaptically and postsynaptically on both
dopamine and nondopamine cells (Meador-Woodruff, 1994).
Dopamine autoreceptors are presynaptic receptors located on
the soma, dendrites, and nerve terminals of dopamine cells
(Wolf & Roth, 1990) . When the autoreceptors on the soma or
dendrites are stimulated, the firing rate of the dopamine
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neuron decreases (Wu, Reith, Walker, Kuhm, Carroll, &
Garris, 2002). When the autoreceptors on the nerve
terminals are stimulated, dopamine synthesis and release is
diminished (Wu et al., 2002). Postsynaptic receptors are
found on nondopamine cells such as GABA and acetylcholine
neurons (Cooper et al., 1996).
Inactivation of dopamine after release is accomplished
by the dopamine transporter (DAT) in the membrane of
presynaptic neurons (Gainetdinov, Jones, Fumagalli,
Wightman & Caron, 1998; Giros & Caron, 1993). DAT plays a
significant role in the removal of extracellular dopamine,
thereby regulating synaptic neurotransmitter concentration
(Gainetdinov et al., 1998; Giros & Caron, 1993). After
reuptake into the nerve terminal, dopamine may be
metabolized by monoamine oxidase (MAO) and converted to
DOPAC or repackaged into synaptic vescicles and re-released
(Cooper et al., 1996; Meador-Woodruff, 1994). Within the
synaptic cleft, dopamine may be converted by catechol-O-
methyltransferase (COMT) into homovanillic acid (HVA)
(Cooper et al., 1996; Meador-Woodruff, 1994).
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Dopamine Receptor System
Dopamine receptors are divided into two families, Dx-
like or D2-like receptors. Di-like and D2-like receptors
were originally differentiated by their biochemical
characteristics. Activation of Di-like receptors leads to
increased activity of adenylyl cyclase and stimulation of
phosphoinositide activity .(Hille, 1992). D2-like receptors,
on the other hand, inhibit adenylyl cyclase activity, 
inhibit calcium (Ca2+) release into nerve terminals, 
increase potassium (K+) conductance, and decrease the 
metabolism of phosphoinositide (Steketee, 2003; Surmeier,
Bargas, Hemmings, Nairn, & Greengard, 1995).
Di-like and D2-like receptors can be further divided
into subtypes. There are currently two subtypes of Di-like
receptors, Di and D5, and four subtypes of D2-like
receptors, D2 short, D2 long, D3, and D4 (Cooper et al.,
1996). These subtypes have been identified through gene
cloning studies, and are differentiated by their relative
distribution in the nervous system. The highest density of
Di receptors are found in the caudate-putamen of the
neostriatum, in mesolimbic structures, which include the
nucleus accumbens and olfactory tubercles, in the ventral
9
tegmental area, and in the substantia nigra pars compacts
(Bardo & Hammer, 1991). The level of D5 receptors are very
low in brain, and are only found in the hippocampus, the
hypothalamus and the parafascicular nucleus of the thalamus
(Lidow, Goldman-Rakic, Gallager, & Rakic, 1991; Meador-
Woodruff, Mansour, Grandy, Damask, Civelli, & Watson,
1992). D2 receptors are found in highest concentration in
the caudate-putamen, nucleus accumbens, olfactory tubercle,
substantia nigra pars compacts, and olfactory bulbs
(Gehlert, Gackenheimer, Seeman, & Schaus, 1992). D3
receptors are localized in the islands of Calleja, a dense
group of small neurons within the olfactory tubercles, and
the nucleus accumbens (Gelhert et al., 1992). D4 receptors
are in the highest concentration in the frontal cortex,
hypothalamus, thalamus, midbrain, medulla, amygdala and
olfactory bulbs (Tarazi, Campbell, Yeghiayan, &
Baldessarini, 1998).
All dopamine receptors are G-protein-coupled guanosine
triphosphate (GTP-binding protein) receptors (Missale,
Nash, Robinson, Jaber, & Caron, 1998; Seamans & Yang,
2004). Stimulation of a dopamine receptor precipitates a
sequence of biochemical actions that begin with activation
of a G-protein in the membrane. Di-like receptors are
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coupled to stimulating G-proteins (Gs or Goif) and, when
activated, adenylyl cyclase activity is facilitated (Cooper
et al., 1996). D2-like receptors are coupled to inhibitory
G-proteins (G± or Go) and when they are activated, adenylyl
cyclase activity is inhibited (Cooper et al., 1996). The
activation and inhibition of adenylyl cyclase activity
precipitates a cascade of events in the cyclic adenosine
monophosphate (cAMP) system, which plays an important role
in neuropharmacological responses to changes in the
dopamine system (Tzschentke, 2001).
More specifically, Gs- and the Goif-proteins activate an
effector protein, adenylyl cyclase, which is the catalyst
in the conversion of adenosine triphosphate (ATP) to cAMP
(Pierce, Premont, & Lefkowitz, 2002). On the other hand,
Gi~and Go-proteins inhibit the effector protein, adenylyl
cyclase, leading to decreases in cAMP (Pierce et al.,
2002). cAMP- functions as a second messenger and activates
the enzyme, protein kinase A (PKA). PKA is a catalyst for
phosphorylation, the transfer of phosphate groups (PO3) from
ATP to specific sites in the cell, and leads to changes in 
Ca2+ and K+ permeability of the cell membrane. The flow of 
Ca2+ and K+ across membrane channels is responsible for
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neuronal firing, the basis of cell signaling and
communication (Grady, Bohm, & Bunnett, 1997).
The cAMP system can be modified after denervation or
prolonged exposure to receptor agonists, resulting in the
system being either up- or down-regulated, respectively
(Terwilliger, Beitner-Johnson, Sevarino, Crain & Nestler,
1991). Down-regulation is characterized by a decrease in
the levels of adenylyl cyclase and PKA activity. The cAMP-
dependent PKA pathway is positively coupled to Di-like
receptors and the desensitization of Di-like receptors leads
to a decrease in PKA activity, or down-regulation (Zhuang,
Belluscio, & Hen, 2000). Alternatively, the cAMP-dependent
PKA pathway is negatively coupled to D2-like receptors,
therefore sensitization of these receptors also lead to
down-regulation and a decrease of PKA activity (Dohovics,
Janaky, Varga, Saransaari, & Oja, 2003b; Terwilliger et
al., 1991). When the number of Di-like receptors or
receptor binding increases, or the number of D2-like
receptors or receptor binding decreases, cAMP is up-
regulated and the levels of adenylyl cyclase and PKA
activity are enhanced. (Grady et al., 1997; Terwilliger et
al., 1991; Tzschentke, 2001).
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Several pharmacological compounds have been developed
that are fairly selective for dopamine receptors. Dopamine
agonists bind to the dopamine receptor and are able to
directly stimulate the receptor, often having a greater
affinity for the receptor site than dopamine (Cooper et
al., 1996). Dopamine antagonists also bind to the dopamine
receptor, but do not stimulate the receptor (Cooper et al.,
1996; Seeman & VanTol, 1994). A prototypical agonist for
Di-like receptors (Di and D5) is SKF-38393 and a
prototypical antagonist is SCH-23390 (Bischoff, Heinrich,
Sonntag & Krauss, 1986; Pierce, Born, Adams, Kalivas,
1996). For the D2 receptor, apomorphine, bromocriptine and
quinpirole are typical agonists and haloperidol, sulpiride,
and spiperone are typical antagonists. Quinpirole,
pergolide, and 7-OH-DPAT are D3 agonists and UH232 is a D3
antagonist. The prototypical agonist for the D4 receptor is
PD168077 and the prototypical antagonist is clozapine
(Cooper et al., 1996; Seeman & Van Tol, 1994).
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CHAPTER 3
GLUTAMATE SYSTEM
Glutamate Synthesis and Transmission
Glutamate is the primary excitatory neurotransmitter
in the central nervous system and is vital for the
maintenance and regulation of brain functions and neural
development (Bordi & Ugolini, 1999; Conn & Pin, 1997;
Nakanishi & Masu, 1994; Wolf, 1998). There are two sources
from which glutamate is synthesized. The first involves
the transformation of glucose through the Krebs cycle and
provides the main source of glutamate within the central
nervous system. The second is from the synthesis of
glutamine in glial cells, which is transported into nerve
terminals where glutaminase converts it into glutamate
(Cooper et al., 1996).
Glutamate is stored in synaptic vesicles of glutamate
nerve terminals (Conn & Pin, 1997; Cooper et al., 1996,).
A Ca2+-dependent exocytotic process releases glutamate into 
the synapse upon depolarization of the nerve terminal
(Cooper et al., 1996). Glutamate in the synaptic cleft is 
mostly removed by glial-type (GT[g]) glutamate transporters 
located on glial cells (Chaudhry, Lehre, van Lookeren
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Campagne, Otterson, Danbolt, & Storm-Mathisen, 1996). A
smaller fraction of extracellular glutamate is removed by
neuronal-type (GT[n]) glutamate transporters, located on the
plasma membrane of the presynaptic nerve terminal (Chaudhry 
et al., 1996) . Upon reuptake by GT[g] transporters into 
glial cells, glutamate is converted by glutamine synthetase
into glutamine and is transported back into a glutamate
nerve terminal where it can be synthesized into glutamate
(Cooper et al., 1996). Glutamine can also be oxidized into
a-ketoglutarate and transported into the neuron to replace
the a-ketoglutarate that is used during the synthesis of
neuronal glutamate through the Krebs cycle (Cooper et al.,
1996).
Glutamate Receptor System
There are two classes of glutamate receptors,
ionotropic and metabotropic. Ionotropic glutamate
receptors (iGluRs) are ligand-gated cation channels that
are involved in fast excitatory neurotransmission (Wolf,
1998). These ion channel-linked receptors are further
divided into N-methyl-D-aspartate (NMDA) receptors, kainate
(KA) receptors, and amino-3-hydroxy-5-methyl-4-isoxazole
propionic acid (AMPA) receptors (Conn & Pin, 1997; Dale,
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Babwah, & Stephen, 2002; Rao, Jean, & Kessler, 1997;).
Originally, iGluRs were thought to be the only glutamate
receptors and the long-term effects of the glutamatergic
system were thought to require activation of other
neurotransmitter receptors such as dopamine, acetylcholine,
serotonin, and norepinephrine (Mao & Wang, 2002a). It was
later discovered that there existed a class of glutamate
receptors that are coupled to G-proteins. These receptors
mediate slower glutamate responses and are called
metabotropic glutamate receptors (mGluRs) and constitute a
large family of receptors coupled to various intracellular
signal transduction systems (Conn & Pin, 1997; Lopez-
Bendito, Shigemoto, Fairen, & Lujan, 2002; Mao & Want,
2002b). MGluRs are located at pre-synaptic and post-
synaptic sites and regulate both the release of glutamate
and the excitation of the post-synaptic membrane (Dale et
al., 2002).
Our understanding of glutamatergic neurotransmission
has been greatly altered by the discovery of mGluRs,
because these receptors have the ability to transform short
neuronal activation into long-lasting changes in synaptic
activity. Glutamate, through mGluRs, can modify or fine-
tune activity at the same synapses responsible for fast
16
synaptic responses. This characteristic makes them an
essential mechanism in synaptic plasticity (Conn & Pin,
1997; Dale et al., 2002).
There are currently a total of eight known subtypes
within the mGluR family, labeled mGluRl through mGluR8
(Conn & Pin, 1997). These subtypes are classified into
three groups based on sequence homology, pharmacology and G
protein-coupling specificity, which define the transduction
mechanism (Conn & Pin, 1997; Cooper et al., 1996; Lopez-
Bendito et al., 2002). Group I mGluRs, which include
mGluRl and mGluR5, are linked through Gq to
phosphoinositide hydrolysis and Ca2+-mediated signal 
transduction. Phosphoinositide hydrolysis involves the
stimulation of phospholipase C, which increases
intracellular inositol 1,4,5-triphosphate (InsP3)
concentrations, releases intracellular Ca2+, and activates 
protein kinase C (PKC) (Pickering et al., 1993). Through
Gs, Group I mGluRs activates adenylyl cyclase which results
in cAMP formation, activating protein kinase A (PKA)
activity (Dohovics, Janaky, Varga, Hermann, Saransaari, &
Oja, 2003a). Both Group II mGluRs, consisting of mGluR2
and mGluR3, and Group 3 mGluRs, consisting of mGluR4,
mGluR6, mGluR7, and mGluR8, are negatively coupled to
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adenylyl cyclase (Conn & Pin, 1997; Dale et al., 2002;
Lopez-Bendito et al., 2002).
The development of drugs that specifically target
mGluRs and their various subtypes has led to a greater
understanding of the function of mGluRs in the nervous
system. The prototypic agonists for the Group I mGluRs are
quisqualate and 3,5-dihydroxyphenylglycine (3,5-DHPG) and
the prototypic antagonists are a-methyl-4-
carboxyphenylglycine (MCPG) and two derivatives of
phenylglycine, .(S)-4-carboxyphenylglycine ((S)-4CPG) and
(S)-4-carboxy-3-hydroxyphenylglycine ((S)-4C3HPG) (Ito et
al., 1992; Hayashi et al., 1994). Compared to mGluRl,
mGluR5 is less sensitive to the antagonists (S)-4CPG and
(S)-4C3HPG, but shows similar affinity to MCPG (Hayashi et
al., 1994). For the Group II mGluRs, a prototypic agonist
is 2R, 4R-4-aminopyrrolidone-2,4-dicarboxylate (APDC)
(Hayashi et al., 1994). Phenylglycine derivatives are
competitive antagonists for this receptor group, with the
most potent being a-methyl-4-phosphonophenylglycine (MPPG)
and a-methyl-4-sulfonophenylglycine (MSPG) (Hayashi et al,
1994). The prototypic agonist for Group III mGluRs is L-
amino-4-phosphonobutyrate (L-AP4) and the prototypic
18
antagonist is a-methyl-L-amino-4-phosphonobutyrate (MAP4)
(Hayashi et al, 1994).
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CHAPTER 4
EFFECTS OF AMPHETAMINE ON DOPAMINE 
AND GLUTAMATE SYSTEMS
Effects of Amphetamine
Dopamine System
Amphetamine is a psychostimulant that increases the
synaptic release of the monoamines, dopamine,
norepinephrine and serotonin (Koob & Bloom, 1998; Self &
Nestler, 1995). Amphetamine primarily works by reversing
the transport of monoamines by binding to monoamine
reuptake transporters, especially the dopamine transporter
(DAT) (Kalivas & Stewart, 1991; Pierce & Kalivas, 1997;
Weiss & Koob, 2001). In addition, amphetamine also blocks
monoamine reuptake and inhibits monoamine oxidase (Genova,
Berke & Hyman, 1997; Vanderschuren & Kalivas, 2000). The
increased release of monoamines, primarily dopamine, is
believed to be the reason amphetamines are pleasurable and
abused by humans (Pierce & Kalivas, 1997; Robinson &
Berridge, 1993; Self & Nestler, 1995). A single
administration of amphetamine is capable of stimulating
extracellular dopamine release and causes dose-dependent
elevations of dopamine in the brain (Pierce & Kalivas,
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1997) . Amphetamine, at doses of 1.0, 3.0, and 9.0 mg/kg,
are capable of elevating extracellular dopamine levels to
700%, 800%, and 1300% of basal levels, respectively
(Kankaanpaa, Meririnne, Lillsunde, & Seppala, 1998). The
displacement of dopamine from storage vesicles, inhibition
of monoamine oxidase, and the blocking of reuptake
transporters suggests that amphetamine is capable of
producing neurotoxic effects on brain pathways (Pierce &
Kalivas, 1997; Weiss & Koob, 2001). In addition, the
massive release of serotonin from presynaptic vesicles
leads to an eventual depletion of serotonin in cells and
further contributes to the neurotoxic effects of
amphetamine (Labarca et al., 1995; Kankaanpaa et al.,
1998) . Behavioral studies show that acute low to medium
doses of amphetamine administered to rats lead to an
increase in locomotor activity, while high doses of the
psychostimulant can induce stereotypy, such as compulsive
licking and gnawing (Kalivas & Stewart, 1991; Robinson &
Becker, 1986). Acute administration of amphetamine can
also lead to an enhanced sensitivity to stressful stimuli,
a decreased response to natural reinforcers, and a
decreased threshold for helplessness (Volkow et al., 2002)
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Glutamate System
Amphetamine also causes an increase in extracellular
glutamate (Karler, Chaudhry, Calder & Turkanis, 1990;
Labarca et al., 1995; Wolf & Xue, 1998). There are several
explanations for the increase in glutamate activity after
systemic administration of amphetamine. Glutamate reuptake 
may be affected by Di receptor stimulation of sodium (Na+) 
and K+ gated channels in neuronal cells (Wolf & Xue, 1998) . 
Amphetamine may also increase Ca2+-independent glutamate 
release through "hypoxia-induced reversal" of the glutamate
reuptake transporter (Del Arco, Gonzalez-Mora, Armas, &
Mora, 1999; Vanderschuren & Kalivas, 2000). In addition,
the reuptake of glutamate may be blocked or impeded by a
number of agents such as: oxygen radicals, nitric oxide, or
arachidonic acid, which remains in the extracellular space
following amphetamine administration (Wolf & Xue, 1998).
The role of mGluR5 in psychostimulant-induced effects
has been examined using mGluR5-null mutant mice. In these
mice, cocaine does not increase locomotor activity,
suggesting that mGluR5s contribute significantly to
psychostimulant-induced locomotor activity (Chiamulera et
al., 2001). Interestingly, the absence of mGluR5 receptors
did not affect either basal dopamine levels or cocaine-
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induced increases in dopamine levels. In addition, the
distribution and expression of dopamine receptors and DAT
did not differ between wild-type and mGluR5-null mutant
mice. These results call into question the functional
relationship between dopamine receptors, mGluR5 receptors,
and the effects of psychostimulants on these systems
(Chiamulera et al., 2001).
Interactions Between mGluR and 
Dopamine Systems
Interestingly, it appears that many of the behavioral
effects of mGluR activation are dependent on the dopamine
system. For instance, activation of dorsal striatal mGluRs
induce dopamine-mediated contralateral turning behavior.
This is based on the observation that dose-dependent
activation of mGluRs enhances the release of dopamine in
the striatum. During periods of hyperstimulation, however,
activation of mGluRs result in a reduction of dopamine
release (Smith & Beninger, 1996; Verma & Moghaddam, 1998;
Wolf, 1998). Additional evidence of this mGluR/dopamine
interaction is the finding that dopamine antagonists
attenuate locomotor activity induced by the mGluR agonist,
1-aminocyclopentane-l,2-dicarboxylic acid (1S,3R-ACPD) (Kim
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& Vezina, 1997; Kim & Vezina, 1998a; Meeker, Kim, & Vezina,
1998). These findings, along with the fact that output
neurons in the nucleus accumbens express both dopamine and
mGluR receptors, suggest that the mGluR system works in
synergy with dopaminergic inputs through intracellular
signaling pathways to influence the effects of
psychostimulants (Kim, Beeler, & Vezina, 2000; Kim &
Vezina, 1998a; Kim & Vezina, 1999; Mao & Wang, 2002c;
Vezina & Kim, 1999).
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CHAPTER 5
BEHAVIORAL SENSITIZATION
Overview
When a psychostimulant (e.g., amphetamine,
methylphenidate, and methamphetamine) is repeatedly
administered to rodents, distinct enduring behavioral
changes occur. One type of change that can occur is a
decline in the effectiveness of the psychostimulant to
affect behavior, a phenomenon referred to as tolerance
(Kalivas & Stewart, 1991; Robinson & Becker, 1986).
Alternatively, repeated psychostimulant treatment can cause
an enhanced response known as reverse tolerance, or
behavioral sensitization. Behavioral sensitization
typically occurs with repeated, intermittent exposure to a
psychostimulant, especially with doses in the low to
moderate range (Kalivas & Stewart, 1991). This enhanced
behavioral response is usually progressive, and can persist
for days, weeks, months, and even years after the last drug
administration (Kalivas & Stewart, 1991; Robinson & Becker,
1986; Steketee, 2003). This response persistence has been
associated with the craving related to drugs of abuse,
which may lead to relapse despite a prolonged period of
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abstinence (Kalivas & Stewart, 1991; Robinson & Becker,
1986).
The process of behavioral sensitization involves two
stages referred to as induction and expression (Kalivas &
Stewart, 1991; Pierce & Kalivas, 1997; Robinson & Becker,
1986; Vanderschuren & Kalivas, 2000). In the induction
phase, the sensitized response develops and is indicated by
a progressive increase in behavioral responding after each
repeated drug administration. The expression of behavioral
sensitization is indicated by an enhanced behavioral
response to an acute drug administration (i.e., challenge
injection) after repeated pre-exposure to the drug (Pierce
& Kalivas, 1997; Robinson & Becker, 1986).
Neural Basis of Behavioral Sensitization
Role of the Dopamine System
The behavioral change to repeated psychostimulant
administration is, in part, due to the neuroadaptive nature
of the mesolimbic and nigrostriatal dopamine system (Pierce
& Kalivas, 1997). The mesolimbic dopamine pathway extends
from the ventral tegmental area (VTA) of the midbrain to
the nucleus accumbens (Nac), prefrontal cortex (PFC) and 
amygdala, and has been demonstrated to partially mediate
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the expression of behavioral sensitization (Genova et al.,
1997; Pierce & Kalivas, 1997). It has recently been shown
that repeated administration of amphetamine may completely
block long-term depression (LTD), a persistent decrease in
excitatory synaptic transmission, in the excitatory
synapses of VTA neurons, and may contribute to the
initiation of the sensitization process (Jones, Kornblum, &
Kauer, 2000). In addition, the long lasting expression of
sensitization has been attributed to adaptations in the
neurons of the nucleus accumbens as well (Pierce & Kalivas,
1997; Robinson & Kolb, 1997).
Neuroadaptations caused by repeated amphetamine
treatment include a transient decrease in the sensitivity
of dopamine autoreceptors found on the cell body and
dendrites of dopaminergic neurons, and a longer lasting
supersensitivity of dopamine Di receptors in striatal
neurons (Kalivas & Stewart, 1991; Robinson & Becker, 1986).
It has been demonstrated that dopamine Di receptors are
critical in the induction of behavioral sensitization to
amphetamine, because amphetamine sensitization is inhibited
when Di receptor antagonists are administered systemically
or intra-cranially to the VTA, (Hamamura et al., 1991;
Ujike, Onoue, Akiyama, Hamamura, & Otsuki, 1989;
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Vanderschuren & Kalivas, 2000). However, most of these
studies have used SCH-23390 to block Di receptors, leaving
open the possibility that non-specific actions of SCH-23390
(i.e., its effects on serotonin (5-HT2) receptors) may
contribute to the prevention of amphetamine sensitization
(Bischoff et al., 1986). Di receptor agonists have been
used to further examine the importance of Di receptors for
the development of sensitization. When SKF-38393, a Di
receptor agonist, is repeatedly administered into the VTA,
behavioral sensitization to cocaine and amphetamine is
produced (Pierce et al., 1996). When cholera toxin, a
compound which activates adenylyl cyclase much like the
stimulation of Dx receptors is administered intra-VTA, the
behavioral effects caused by acute amphetamine
administration are heightened and the development of
amphetamine-induced sensitization is magnified (Byrnes,
Weinstein, & Wallace, 1997).
Alternatively, sensitization to amphetamine has been
demonstrated to occur through mechanisms not involving
dopamine Di receptors. Evidence for Di receptor-independent
amphetamine sensitization has been demonstrated through the
use of Di receptor knockout mice. Although lacking
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functional Di receptors, these animals readily develop
amphetamine sensitization (Karper et al., 2002).
Dopamine D2 receptors may also be involved in the
development of amphetamine-induced sensitization, but their
function is less clearly defined. For example, amphetamine
sensitization is blocked when D2 antagonists, such as
haloperidol, clozapine, YM-09151-2 and nemonapride, are
administered (Bjijou, Stinus, Le Moal, & Cador, 1996;
Hamamura et al., 1991). Other D2 receptor antagonists, such
as pimozide and spiperone, did not block amphetamine
sensitization, and studies using sulpiride have provide •
inconclusive results (Karler et al., 1990; Vanderschuren &
Kalivas, 2000) .
Role of the Glutamate System
Although there is a substantial amount of evidence
suggesting that the dopamine system plays a pivotal role,
modifications in the dopamine system are not solely
responsible for the development of behavioral sensitization
(Wolf, White, & Hu, 1994). For instance, the enhanced 
I
behavioral effects of amphetamine can be blocked by
administration of glutamate NMDA antagonists such as MK-801
(Karler et al. , .1990; Wolf & Xue, 1998). Moreover,
repeated psychostimulant administration elevates glutamate
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transmission in both the Nac and the VTA (Churchill,
Swanson, Urbina, & Kalivas, 1999; Sesack, Deutch, Roth, &
Bunney, 1989; Vanderschuren & Kalivas, 2000).
MGluRs also play an integral part in the induction and
expression of psychostimulant-induced behavioral
sensitization (Attarian & Amalric, 1997; Darracz, Drouin,
Blanc, Glowinski & Ta.ssin, 2001; Kim & Vezina, 1998b; Kim &
Vezina, 1998c; Nicoletti et al., 1999; Vezina & Kim, 1999;
Wolf, 1998). Repeated psychostimulant administration
increases the expression of mGluR5 in the nucleus
accumbens, the VTA, and the caudate of the dorsolateral
striatum (Ghasemzadeh, Nelson, Lu, & Kalivas, 1999). This
elevated level of mRNA encoding mGluR5 suggests that
metabotropic glutamate receptors may have a significant
role in psychostimulant-induced sensitization; however,
little information currently exists on the regulation of
mGluR5 function after repeated psychostimulant
administration (Wolf & Xue, 1998; Xue, Ng, Li, & Wolf,
1996) . 1
Recent studies have found that the development of
amphetamine sensitization can be blocked by intracranial-
VTA administration of an mGluR antagonist (Darracz et al. ,
2001; Kim & Vezina, 1998b; Kim & Vezina, 2000; Vezina &
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Kim, 1999). Amphetamine-induced locomotion is blocked by
intracranial-Nac injections of the mGluR5 antagonist, (RS)-
methyl-4-carboxyphenylglycine (MCPG) (Attarian & Amalric,
1997; Kim & Vezina, 1998a; Wolf, 1998) and intracranial-VTA
injection of MCPG blocks the development of amphetamine-
induced locomotor sensitization (Kim & Vezina, 1998b; Wolf,
1998) .
These studies indicate that the development of
psychostimulant-induced sensitization involves the
glutamate system, more specifically, activation of
metabotropic glutamate receptors, in addition to the
dopamine system. Demonstrating that metabotropic glutamate
receptors play a role in mediating psychostimulant-induced
behavioral sensitization has revealed an interesting
functional interaction between the dopamine system and
metabotropic glutamate receptors (Ohno & Watanabe, 1995;
Sacaan, Bymaster & Schoepp, 1992; Sacaan, Monn & Schoepp,
1991) .
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CHAPTER 6
ONTOGENY OF RECEPTOR SYSTEMS AND 
BEHAVIORAL SENSITIZATION
Ontogeny of Dopamine Receptors
Dopamine receptors undergo substantial changes across
the neonatal period (Gelbard, Teicher, Faedda &
Baldessarini, 1989; Murrin & Zeng, 1990; Rao, Molinoff &
Joyce, 1991) . In general, both dopamine Di and D2 receptors
are at low levels at birth and are first detectable in
regions such as the prefrontal cortex, striatum, caudate-
putamen, and olfactory tubercles (Murrin & Zeng, 1990). In
these brain regions, dopamine receptor levels increase
sharply after birth, reaching adult levels at approximately
postnatal day 25 (Andersen, Thompson, Rutstein, Hostetter,
& Teicher, 2000). Receptor density then continues to
increase, rising above adult levels, until the onset of
puberty at postnatal day 40 (Andersen et al., 2000; Tarazi
& Baldessarini, 2000). Following this overexpression,
dopamine receptors undergo the process of pruning in which
receptor levels gradually decline to adult levels by
postnatal day 60 and remain relatively constant throughout
adulthood (Tarazi & Baldessarini, 2000). In the nucleus
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accumbens, low levels of dopamine receptors are also
detectable at birth. Dopamine receptors in these regions
begin to increase around postnatal day 10 and reach maximum
levels by postnatal day 40 (Teicher, Andersen, & Hostetter,
1995). Receptor levels remain constant thereafter, without
the process of pruning (Anderson et al., 2000; Teicher et
al., 1995).
Ontogeny of Metabotropic Glutamate Receptors
Studies using in situ hybridization and
autoradiographic binding techniques have revealed that
mGluR5 is present at birth and reaches peak levels at
approximately postnatal day 10 in the striatum and frontal
cortex (Catania, Landwehrmeyer, Testa, Standaert, Penney, &
Young, 1994; Romano, Smout, Miller & O'Malley, 2002). The
expression of mGluR5 protein then gradually decreases over
the course of development until the animal reaches
adulthood (postnatal day 60), at which point the level of
mGluR5 mRNA stabilizes (Romano et al., 2002; Romano, Van
den Pol, & O'Malley, 1996). This change is most pronounced
in the cortex, hippocampus, midbrain/thalamus and striatum
(Romano et al., 1996). Developing mGluR5 receptors
function similarly to adult receptors, however, the
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stimulation of phosphatidyl inositide hydrolysis is more
enhanced in the developing (postnatal day 10) brain than in
the adult (postnatal day 60) brain (Palmer, Nangel-Taylor,
Krause, Roxas, & Cotman, 1990; Sacaan, Santori, & Rao,
1998; Sortino, Nicoletti, & Canonico, 1991; Van den Pol,
Romano, & Ghosh, 1995).
Ontogeny of Behavioral Sensitization
The acute administration of psychostimulants causes a
similar dose-response curve in developing and adult rats
(Tirelli et al., 2003). Low to moderate doses (0.2 - 1.0
mg/kg) of amphetamine produce an increase in locomotor
activity and a high dose (5.0 mg/kg) produces stereotypic
licking and gnawing (Porrino, Lucignani, Dow-Edwards, &
Sokoloff, 1984; Tirelli et al., 2003). In contrast,
repeated psychostimulant treatment has different effects in
developing and adult rats. Early studies found that rats
tested prior to and during weaning were unable to express
behavioral sensitization to repeated cocaine or amphetamine
administration (Barr& Wang, 1993; Fujiwara, Kazawaya,
Nakashima, Sato, & Otuki, 1987; Kolta, Scalzo, Ali, &
Holson, 1990). Later it was discovered that
psychostimulant-induced sensitization can be achieved in
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developing rats by: (1) consistently pairing the drug
administration and testing environment; (2) extending the
number of pre-exposure days; and (3) minimizing the length
of the drug abstinence period (McDougall et al., 1994;
Tirelli & Ferrara, 1997; Tirelli et al., 2003; Wood et al.
1998; Zavala, Nazarian, Crawford, & McDougall, 2000).
These later studies found that young rats can readily
express sensitization if testing occurs within 24 hr to 48
hr after the last pretreatment injection (i.e., short-term
sensitization). However, the expression of long-term
sensitization (testing occurring 1 week or more after the
last pretreatment injection) requires an extended
pretreatment period and is much weaker than that observed
in adult rats (Tirelli & Ferrara, 1997; Zavala et al.,
2000). The less robust long-term effects of repeated drug
administration in the young rat has been attributed to age
related neurobiological maturation (i.e. receptor density
I
and functioning), which may contribute to the change in
response to the psychopharmacological action of drugs
(Tirelli et al., 2003).
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Summary
Dopamine receptor levels appear to mature quickly,
therefore the involvement of dopamine receptors in the
developmental differences of behavioral sensitization
between young and adult rats may be minimal. However, the
differential expression of mGluR5 across ontogeny may play
an important role in the developmental changes of
behavioral sensitization. Although mGluR5 is important for
the development of sensitization in the adult rat (Attarian
& Amalric, 1997; Darracz et al., 2001; Kim '& Vezina, 1997;
Kim & Vezina, 1998a; Kim & Vezina, 1998b; Kim et al., 2000;
Wolf, 1998), the role mGluR5 plays in behavioral
sensitization in the preweanling rat has not yet been
studied. Further investigation is needed to understand the
possible involvement, of mGluR5 in the neuroadaptations that
follow repeated psychostimulant administration in the
developing rat.
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CHAPTER 7
SUMMARY AND EXPERIMENTAL HYPOTHESES
Summary and Purpose
The induction and expression of psychostimulant-
induced behavioral sensitization differs between developing
and adult rats. Both short- and long-term sensitization can
be readily induced and expressed in adult animals, but in
developing animals, the induction and expression of long­
term sensitization cannot be consistently reproduced and is
often only weakly detected (Tirelli & Ferrara, 1997; Zavala
et al., 2000). Although the cause of this developmental
difference is unknown, it is possible that immaturity in
the glutamate systems is responsible. Specifically,
metabotropic glutamate receptors have been shown to be
immature at birth and undergo substantial changes during
the early postnatal weeks. These changes in the density
and efficacy of glutamate binding sites on metabotropic
glutamate receptors may contribute to the ontogenetic
differences of behavioral sensitization. In adult rats,
administration of an mGluR5 antagonist (i.e., MCPG) blocks
the development of behavioral sensitization. At present,
the effect of MCPG on behavioral sensitization in the
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developing rat has not yet been investigated. Therefore in
the present study, MCPG was administered to rat pups to
determine if amphetamine-induced behavioral sensitization
would be affected by metabotropic glutamate receptors.
Experimental Overview
A behavioral dosing paradigm previously shown to
induce short-term behavioral sensitization in young rats
was used. During the pretreatment phase of the experiment,
rats received amphetamine or saline in combination with a
low dose of MCPG (2.5 nM), a high dose of MCPG (25.0 nM) or
no MCPG (0.0 nM). Two doses of MCPG were used to determine
whether this antagonist has a dose-dependent effect on
amphetamine-induced behavior. All animals received the
pretreatment for 5 consecutive days and behavioral activity
was recorded on each day following drug administration. A
test day occurred 48 hours after the last pretreatment
(i.e., after 1 drug abstinence day). Animals pretreated
with saline received a challenge injection of either saline
or amphetamine, and animals pretreated with amphetamine
were challenged with a challenge injection of amphetamine
only, and locomotor activity was measured. Groups are
summarized in Table 1.
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Table 1: Summary of Treatment Groups
Pretreatment (5 days)
3 MCPG doses 
(SAL, MCPG (2.5), MCPG 
(25) )
2 AMPH doses 
(SAL, AMP 
(2mg/kg))
Challenge 
inj ection 
(SAL, AMP 
(0.5mg/kg))
Group
SAL SAL
SAL G1 (n=10)
AMP G2 (n=10)
AMP AMP G3 (n=10)
MCPG (2.5nM) SAL
SAL G4 (n=10)
AMP G5 (n=10)
AMP AMP G6 (n=10)
MCPG (25nM) SAL
SAL G7 (n=10)
AMP G8 (n=10)
AMP AMP G9 (n=10)
Hypotheses
During the pretreatment phase it was predicted that
the induction of behavioral sensitization would occur in
rats receiving repeated amphetamine treatment and no MCPG,
as demonstrated by a progressive increase in locomotor
activity after each drug exposure day. It was also
expected that, in contrast with studies on adult rats, the
induction of behavioral sensitization would not be
attenuated in rat pups receiving repeated amphetamine
treatment in combination with a low or a high dose of MCPG.
During the challenge phase it was expected that rat pups
pretreated with amphetamine and no MCPG and challenged with
amphetamine would exhibit a significantly higher level of
activity relative to rats receiving an acute amphetamine
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challenge (i.e., pretreated with saline and no MCPG and
challenged with amphetamine), indicating behavioral
sensitization. It was also predicted that developing rats,
in contrast to what is seen in adults, would express
behavioral sensitization when challenged with amphetamine
following pretreatment with amphetamine in combination with
either a low or high dose of MCPG The inability of MCPG
to block sensitization in preweanling rats would provide
evidence that the immaturity of metabotroptic receptors is
important in the ontogenetic differences seen in behavioral
sensitization.
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CHAPTER 8
METHODS
Subjects
Subjects were 90 (n=10 per group) 10-day-old male and
female rats of Sprague-Dawley descent (Harlan), born and
raised at California State University, San Bernardino. Rat
pups were kept with dams throughout behavioral testing. No
more than one rat from each litter was placed into a
particular group to control for litter effects. The colony
room was maintained at 21-23°C and kept under a 12-hr
light/dark cycle. All the experiments were approved by the
Institutional Animal Care and Use Committee and met the
International Animal Guide for the Care and Use of
J
Laboratory Animals.
Drugs
(RS)-Methyl-4-carboxyphenylglycine (MCPG; Tocris
Cookson, Inc., Ellisville, MO) was dissolved in saline and
microinjected at a volume of 0.25 pl/side. (+)-Amphetamine
(AMPH; Sigma Aldrich, St. Louis, MO) was mixed in saline 
and injected i.p. at a volume of 5 ml/kg.
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Apparatus
Behavioral testing was conducted in commercially
available (Coulbourn Instruments, Allentown, PA) activity
monitoring chambers (25.5 x 25.5 x 41 cm), consisting of
acrylic walls, a plastic floor, and an open top. A
photobeam array, with 16 photocells and detectors, was used
to measure distance traveled (horizontal locomotor
activity).
Surgery
On postnatal day 10, rats received a 1 ml/kg dose 
(i.p.) of a commercially available solution of ketamine
I
hydrochloride and xylazine hydrochloride. Once a surgical
plane of anesthesia was achieved, rats were placed in a
Cunningham Neonatal Rat Adapter attached to a standard Kopf
stereotaxic apparatus. A single incision was made mid-
sagitally along the skull and the skin retracted. Two
small holes (1.5 mm diameter) were drilled in the skull
using a Dremel Moto tool and stainless steel guide cannulas
(26 gauge) were implanted bilaterally 1.0 mm above the
lateral ventricles (1.0 mm lateral, -2.0 mm ventral, and
+4.4 mm anterior to lambda). Stereotaxic coordinates were
obtained from Sherwood & Timiras, 1970. Commercially
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available super glue gel was used to secure the cannulae in
place. The skin was then glued together with a small
amount of super glue gel. Surgical tools were sterilized
after each surgery. After surgery, stainless steel stylets
were used to seal the cannulae to prevent occlusion until
time of testing. Rats were allowed to recover post-surgery
away from the dam in a temperature-controlled chamber
(30°C) . After each rat pup became fully responsive it was
placed back with the dam. All rats began behavioral
testing 24 hr after surgery. Immediately after behavioral
assessment was finished on the last test day, rats were
sacrificed, and injection sites were verified.
Behavioral Procedure
During the pretreatment phase, injection cannulae (26
gauge) were lowered through the guide cannulae, extending
1.0 mm beyond the guide, into the lateral ventricles.
Injection cannulae w.ere connected with PE20 tubing to a
Hamilton microsyringe which was used to bilaterally
microinject the glutamate antagonist, MCPG (0, 2.5, or 25
nmol) at a volume of 0.25 pi per side. MCPG was delivered
at a constant rate over a 30 s period. Infusion cannulae 
were left in place for an additional 60 s. Fifteen minutes
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following the MCPG infusion, rats were injected with saline
or amphetamine (2 mg/kg) and placed in the testing
apparatus. Locomotor activity was measured for 60 min and
the mean distance traveled was recorded per 5 min time
block. On pretreatment days 1-5, rats received daily
treatments of one intracranial (i.e.) infusion and one
intraperitoneal (i.p.) injection. A single test day
occurred 48 hr after the last pretreatment day. On the
test day, rats pretreated with saline received a challenge
injection of saline or amphetamine (1 mg/kg) and rats
pretreated with amphetamine received a challenge of
amphetamine (0.5 mg/kg). Locomotor activity was measured
for 120 min and mean distance traveled was recorded per 5
min time block. In summary, 9 groups (n=10 per group) of
rats received the following sequence of drugs during the
pretreatment i.e./i.p. - test day i.p. phases (doses are in
parentheses): SAL/SAL - SAL, SAL/SAL - AMP(0.5),
SAL/AMP(2) - AMP(0.5), MCPG(2.5)/SAL - SAL, MCPG(2.5)/SAL -
AMP(0.5), MCPG(2.5)/AMP(2) - AMP(0.5), MCPG(25)/SAL - SAL,
MCPG(25)/SAL - AMP(0.5), MCPG(25)/AMP(2) - AMP(0.5).
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Histology
At the end of behavioral testing, rats were sacrificed
and the brains removed and fixed in 10% formalin for a
minimum of 7 days. Following the fixation period, brains
were sucrose-protected in a 20% sucrose solution for 24 hr.
Coronal sections (75 pm) were cut in a temperature-
controlled cryostat maintained at -25°C. Sections were
mounted and stained with thionin and cannulae placements
were verified.
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I CHAPTER NINE
RESULTS
’Locomotor Activity
Pretreatment Phase 1------------------ i
Mean distance traveled (i.e., locomotor activity) by
Irats pretreated with MCPG (0.0, 2.5, or 25.0 nM, i.e.) and
I
amphetamine (2.0 mg/kg) or saline for five consecutive days
starting on PD 11 are summarized in Table 2. Locomotor
activity is also represented in Figure 1.
iiRats that receiyed no amphetamine and no MCPG
treatments (Gl and G2, in reference to Table 2) and rats
that received repeated amphetamine and no MCPG treatments
I(G3) , are the relevant groups for testing the hypothesis
regarding amphetamine-induced behavioral sensitization inI
the absence of MCPG. I A 2 (AMPH dose) x 5 (pre-exposure
idays) ANOVA for mixed design (with AMPH dose as a between-
subjects variable and pre-exposure days as a within-
subjects variable) involving Gl, G2, and G3 was conducted, 
i
A progressive increase in locomotor activity after each
drug exposure day was observed in both Gl, G2, and the G3
Irats. [Main effect of pre-exposure days: F(4, 112) = 34.89;
p = .000], However, a significantly higher level of
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locomotor activity wa!s observed in the G3 rats (M =
i
1940.40), when compared to the G1 and G2 rats (M =
I
1165.28). [Main effect of AMPH dose: F(l, 28) = 20.98; p =
I
.000]. This suggests jthat the induction of behavioral
I
sensitization occurred following repeated amphetamine
Itreatments. [
1Table 2: Mean Distance Traveled (Standard Error) During 
Pretreatment Period
3
MCPG
dose
2
AMPH
dose
Dl D2
1
D3 D4 D5 MeanD1-D5 Group
SAL
SAL 371.77(102.74)
(
826.95
(192.28)
I
1377.93 
(250.10)
1614.94
(261.46)
1634.83
(243.37)
1165.28
(130.88)
G1
n=10
G2
n=10
AMP
(2)
732.47
(91.83)
1522.56
(240.66)
1896.91
(161.36)
2785.39
(285.32)
2764.69
(307.28)
1940.40
(151.31)
G3
n=10
MCPG
(2.5)
SAL 426.48(100.68)
683.15
(138.11)
1308.42
(306.03)
1599.09
(351.05)
1239.06 
(214.61)
1051.24
(174.65)
G4
n=10
G5
n=10
AMP
(2)
532.47
(78.85)
llO^.lO
(158.42)
1716.78
(136.56)
2092.04
(176.37)
2007.55
(228.06)
1490.99
(113.17)
G6
n=10
MCPG
(25)
SAL 303.15(62.78)
655.43
(138.75)
946.76
(232.84)
'1278.60 
(244.43)
1070.26
(264.42)
850.84
(8143.7)
G7
n=10
G8
n=10
AMP
(2)
550.60
(77.93)
1180.23
(165.87)
1779.11
(159.44)
2356.19
(96.32)
2467.88 
(175.85)
1666.80
(76.77)
G9
n=10
i
i
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Pretreatment
Figure 1. Locomotor Activity During Pretreatment Period. 
Mean (±SEM) distance, traveled for entire testing period of 
rats pretreated with 0.0 nM MCPG (top panel), 2.5 nM MCPG 
(middle panel), or 25.0 nM MCPG (bottom panel) followed 15 
min later by an inje'ction of 2.0 mg/kg amphetamine (filled 
symbols) or saline (open symbols) on five consecutive days 
Behavioral testing lasted 60 min and occurred immediately 
after amphetamine or saline injections. (a) Significantly 
different from rats given saline (open symbols).
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Further analysis; of G3 animals (rats receiving 
repeated amphetamine and no MCPG treatments) and the
progressive increase ;in locomotor activity after each drug 
exposure was made using repeated-measures pairwise
comparisons (Refer to Table 3). The activity level on D5
is approximately equal to the activity level on D4; D5 and
D4 activity levels are significantly greater than DI, D2,
and D3. D3 activity level is greater than D2, but not
significantly greater; while D3 and D2 activity levels are
significantly greater than Di. This set of results further
supports the occurrence of amphetamine-induced behavioral
sensitization.
Table 3: Repeated-Measures Pairwise Comparisons of Rats 
Receiving Repeated Amphetamine and no MCPG Treatments
Day
Mean
(Std. Error)
2 j
1522[56 
(240.66)
3
1896.91
(161.36)
4
2785.39
(285.32)
5
2764.69 
(307.28)
1
732.47
(91.83)
p = .,005 p = .000 p = .000 p = .000
2
1522.56
(240.66)
p = .095 p = .011 p = .011
3
1896.91
(161.36)
p = .003 p = .007
4
2785.39
(285.32)
p = .927
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To test the hypothesis that induction of behavioral
sensitization would not be attenuated in rat pups receiving
repeated amphetamine Treatment in combination with a low or
high dose of MCPG, two 2 (AMPH dose) x 5 (pre-exposure
days) ANOVA for mixed design (with AMPH dose as a between-
subjects variable and pre-exposure days as a within-
subjects variable) were conducted (one for G4 & G5 vs. G6
and the other for G7 & G8 vs. G9). In addition, G3, G6,
and G9 animals were tested using a 3 (MCPG dose) x 5 (pre­
exposure days) ANOVA for mixed design (with MCPG dose as a
between-subject variable and pre-exposure days as a within-
subjects variable). To confirm the hypothesis, the
relative behavioral pattern contrasting G4 & G5 with G6 and
the relative behavioral pattern contrasting G7 & G8 with G9
should resemble the relative behavior pattern observed in
contrasting Gl & G2 with G3. Moreover, when G3, G6, and G9
animals are compared, a significant main effect of pre­
exposure days should be observed; while no significant main
effect of MCPG dose should be observed.
As a control, a 3 (MCPG dose) x 5 (pre-exposure days)
ANOVA for mixed design (with MCPG dose as a between-subject
variable and pre-exposure days as a within-subjects
variable) was also conducted to see how MCPG dose would
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influence rats receiving no repeated amphetamine treatment
(i.e., G1+G2 vs. G4+G5 vs. G7+G8). As can be seen from the
second and third panels in Figure 1 (and the data presented
in Table 2), similar to the G3 rats (that received repeated
amphetamine treatment and no MCPG), a progressive increase
in locomotor activity after each drug exposure day was
observed for the G6 rats (animals that received repeated
amphetamine and a low, 2.5nM, dose of MCPG) as well as for
the G9 rats (animals that received repeated amphetamine and
a high, 25nM, dose of MCPG). [Main effect of pre-exposure
days: F(4,108)= 74.05; p = .000]. Moreover, as illustrated
in Figure 1, when compared to their corresponding
counterparts (i.e., rats receiving the same amount of MCPG,
but with no repeated amphetamine treatments, G6 vs. G4+G5;
G9 vs. G7+G8), the rat pups receiving repeated amphetamine
treatments showed significantly higher levels of locomotor
activity, indicating the development of behavioral
sensitization. [Main effect of AMPH dose: For rats with
low, 2.5nM MCPG-G6 vs. G4+G5, F(l,28)= 5.20, p = .030; for
rats with high, 25nM MCPG—G9 vs. G7+G8, F(l,28)= 27.90, p =
.000.]
Interestingly, the induction of behavioral
sensitization in rat pups receiving repeated amphetamine
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treatments was, to a certain degree, influenced by the
amount of MCPG given in combination with the amphetamine
treatments. [Main effect of MCPG: F(2,27) = 3.70, p =
.038]. As can be seen in Table 4, although the G9 rats
(those'receiving high, 25nM, MCPG, M = 1666.80) expressed a
lower locomotor activity level than the G3 rats (those with
no MCPG, M = 1940.40), the difference was not significant.
On the contrary, the G6 rats (those with low, 2.5nM, MCPG,
M = 1490.99) exhibited a significantly lower locomotor
activity level than the G3 rats (those with no MCPG, M =
1940.40). No significant differences in locomotor activity
levels were observed between the G6 rats (those with low,
2.5nM, MCPG, M = 1490.99) and the G9 rats (those receiving
high, 25nM, MCPG, M = 1666.80), although, in general, the
G6 rats showed a lower level of activity than the G9 rats.
This set of results indicates that the induction of
behavioral sensitization is attenuated, to a certain
degree, in rat pups receiving repeated amphetamine
treatment in combination with a low dose of MCPG (refer to
Figure 1).
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Table 4: Tukey HSD Tests for Rats Receiving Repeated 
Amphetamine Treatments in Combination with no MCPG, a low 
dose (2.5nM) of MCPG, or a high dose (25nM) of MCPG
MCPG Pretreatment Homogeneous SubsetSet 1 Set 2
MCPG (2.5) 1490.99
MCPG (25) 1666.80 1666.80
MCPG (0) 1940.40
When rats with no repeated amphetamine treatment (i.e.,
G1+G2 vs. G4+G5 vs. G7+G8) were compared, the results
indicated that low or high MCPG lowered the rats' locomotor
activity levels; however, the influence was not
statistically significant, F(2, 57) = 2.22, p = .118.
Test Day: Amphetamine Challenge
Mean distance traveled during the entire testing
period for rats receiving a challenge injection of AMPH
(0.5 mg/kg) or saline 48 hr after five consecutive days of
MCPG (0.0, 2.5, or 25.0 nM, i.e.) and AMPH (2.0 mg/kg) or
saline pretreatment is presented in Table 5. Depending on
the type of challenge injection (saline or amphetamine)
received, rat pups pretreated with no MCPG (in combination
with amphetamine or saline (Gl, G2, and G3)) significantly
differed in locomotor activity levels on the test day.
53
[Main effect of Treatment combination: F(2,26) = 21.57; p =
.000] .
Table 5: Mean Distance Traveled (Standard Error) on Test 
Day Following a Challenge Injection of 0.5 mg/kg 
Amphetamine After One Drug Abstinence Day
Pretreatment 
(5 days) Test day
3 MCPG 
doses
2 AMPH 
doses
Challenge 
inj ection Mean Group
SAL SAL
SAL 6155.79 (1637.18) Gl (n = 10)
AMP (0.5mg/kg) 25299.80 (2898.56) G2 (n = 10)
AMP
(2mg/kg) AMP (0.5mg/kg)
29783.61 
(1415.29) G3 (n = 10)
MCPG 
(2.5nM)
SAL
SAL 8070.03 (1661.18) G4 (n = 10)
AMP (0.5mg/kg) 24906.19 (2130.68) G5 (n = 10)
AMP
(2mg/kg) AMP (0.5mg/kg)
27972.65 
(1841.00) G6 (n = 10)
MCPG (25nM)
SAL
SAL 9731.50(3516.75) G7 (n = 9)
AMP (0.5mg/kg) 32033.41 (3473.58) G8 (n = 10)
AMP
(2mg/kg) AMP (0.5mg/kg)
41693.01 
(3729.51) G9 (n = 10)
Further analyses with Tukey HSD tests are presented in
Table 6. Without MCPG, a higher level of locomotor
activity was observed for the G3 rats (those pretreated
with AMPH and challenged with AMPH, M = 29783.61) than the
G2 rats (those pretreated with saline and challenged with
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Table 6: Tukey HSD Tests for Rats Challenged with 0.5 mg/kg 
Amphetamine After One Drug Abstinence Day
MCPG Pretreatment
Homogeneous Subset
Set 1 Set 2
MCPG (0)+saline-saline G1 6155.79
MCPG (0)+saline-AMPH G2 25299.80
MCPG (0)+AMPH-AMPH G3 29783.61
MCPG Pretreatment Homogeneous Subset
Set 1 Set 2
MCPG (2.5)+saline-saline G4 8070.03
MCPG (2.5)+saline-AMPH G5 24906.19
MCPG (2.5)+AMPH-AMPH G6 27972.65
MCPG Pretreatment Homogeneous Subset
Set 1 Set 2
MCPG (25)+Saline-Saline G7 9731.50
MCPG (25)+Saline-AMPH* G8 32033.41
MCPG (25)+AMPH-AMPH G9 41693.01
* 1 missing data
AMPH, M = 25299.80); however, the difference was not
significant. It is important to note that upon reviewing
the distance traveled averaged across all animals in each
treatment group, the standard deviations were very large.
This may be a contributing factor to the absence of
statistical significance between groups, though the
patterns are consistent with the expected sensitized
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response of amphetamine pretreated and amphetamine
challenged rats compared to rats exposed to an acute
exposure of amphetamine on the test day (see Figure 2).
Similarly, for rats pretreated with low MCPG (2.5nM) or
high MCPG (25nM), higher levels of locomotor activity were
observed for those rats pretreated with AMPH and challenged
with AMPH compared to those acutely exposed to AMPH on test
day (G6 vs. G5 and G9 vs. G8); however again, the
differences were not significant.
It was also predicted that developing rats, in
contrast to what is seen in adult rats, would express
behavioral sensitization when challenged with amphetamine
following pretreatment with amphetamine in combination with
either a high or low dose of MCPG. Interestingly, results
indicate that the expression of behavioral sensitization in
rat pups pretreated with amphetamine and challenged with
amphetamine was, to a certain degree, influenced by the
given amount of MCPG. [Main effect of MCPG: F(2,27) =
8.56, p = .001]. As indicated in Table 7, a low dose
(2.5nM) of MCPG reduced the level of locomotor activity
(when compared to no MCPG); however, the effect was not
significant. Surprisingly, instead of blocking the
expression of behavioral sensitization, a high dose (25nM)
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Test Day
Pretreatment (nM)
Figure 2. Locomotor Activity on Test Day. Mean (±SEM) 
distance traveled of rats receiving a challenge injection 
of 0.5 mg/kg amphetamine after one drug abstinence day. 
During the pretreatment phase, rats received daily 
injections of MCPG (0.0, 2.5, or 25.0 nM, i.e.) followed, 
15 min later, by an injection of 2.0 mg/kg amphetamine or 
saline. Behavioral testing lasted 120 min and occurred 
immediately after injections.
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Table 7: Tukey HSD Tests for Rats Receiving a Challenge 
Injection of Amphetamine Following Pretreatment with 
Amphetamine and MCPG
MCPG Pretreatment Homogeneous SubsetSet 1 Set 2
MCPG (2.5)+AMPH-AMPH G6 27972.65
MCPG (0)+AMPH-AMPH G3 29783.61 '
MCPG (25)+AMPH-AMPH G9 41693.01
of MCPG significantly increased the locomotor response to a
challenge injection of amphetamine.
Histology
A representative photomicrograph of a thionin-stained
coronal section with bilateral cannulae tracts is shown in
Figure 3. Schematic illustrations of the locations of
microinjection sites of all the rats included in the data
analyses are shown in Figures 4, 5 and 6.
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1Figure 3. Representative Image 
Section Indicating the Cannulae 
the Lateral Ventricles.
of a Thionin-stained 
Tracts Directed 1 mm Above
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Figure 4. Approximate Locations of the Microinjection 
Sites in the Lateral Ventricles of Rats Included in the 
Data Analyses. Representative line drawing from Paxinos 
and Watson (1994) at -0.40 mm from Bregma.
60
Figure 5. Approximate Locations of the Microinjection 
Sites in the Lateral Ventricles of Rats Included in the 
Data Analyses. Representative line drawing from Paxinos 
and Watson (1994) at -0.80 mm from Bregma.
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iFigure 6. Approximate Locations of the Microinjection 
Sites in the Lateral,Ventricles of Rats Included in the 
Data Analyses. Representative line drawing from Paxinos 
and Watson (1994) at'-0.92 mm from Bregma.
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CHAPTER 10
DISCUSSION
The behavioral response to repeated amphetamine
differs between developing and adult rats. While adult
animals readily develop psychostimulant-induced
sensitization, in developing animals sensitization is only
weakly detected (Tirelli & Ferrara, 1997; Zavala et al.,
2000). Two neurotransmitter systems (dopamine and
glutamate) have been found to be important in the mediation
of behavioral sensitization in adult rats (Pierce &
Kalivas, 1997; Wolf, 1998). Moreover in adult rats, these
systems interact as mGlu receptors regulate amphetamine-
induced locomotor activity and the development of
behavioral sensitization by influencing dopaminergic
neurotransmission (Attarian & Amalric, 1997; Kim & Vezina,
1997, 1998b). In contrast to adult rats, the neurosystems
responsible for behavioral sensitization in the developing
brain are much less understood. Moreover, much of the
developmental studies on behavioral sensitization have
focused on dopamine systems with very little work done on
glutamate systems. Since mGlu receptors have been found to
undergo dynamic changes during early postnatal development,
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it is possible that this change in receptor expression and
function is important in the developmental differences seen
in behavioral sensitization. Therefore, in the present
study, the role of mGluR5 in short-term behavioral
sensitization of preweanling rats was examined.
Specifically, the mGluR5 antagonist, MCPG, was given to
developing rats to block mGlu5 receptors prior to each
repeated amphetamine treatment. It was expected that if
mGlu5 receptors are functionally immature during the
preweanling period, then blocking these receptors with an
antagonist would have no consistent effect on the 1
development of behavioral sensitization. The persistence
of behavioral sensitization to develop despite the
inhibition of mGlu5 receptors would provide evidence for
the contrast between developing and adult animals and the
functional interaction between the metabotropic glutamate
and dopamine systems; in adult behavioral sensitization,
which may be absent in developing animals.
Role of mGluR5 !in the Development of Amphetamine- 
induced Behavioral Sensitization
During the pretreatment phase, amphetamine
administration produced progressively enhanced locomotor
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activity (see Figure 1). This amphetamine-induced
behavioral effect is consistent with previous reports on
the stimulatory effects of a psychostimulant (Kalivas &
Stewart, 1991; Pierce & Kalivas, 1997; Self & Nestler,
1995). Interestingly, pretreatment with a low dose of the
mGluR5 antagonist, MCPG (2.5nM), significantly attenuated
locomotor activity of the amphetamine-treated rats; while a
high dose of MCPG (25nM) did not significantly attenuate
these amphetamine-treated rats. MCPG also attenuated
locomotor activity of the saline-treated rats; however, the
influence was not statistically significant. (See middle
and bottom panel of Figure 1.) This set of findings
concerning amphetamine-induced behaviors observed in
preweanling rats is in contrast with previous studies of
adult rats in which MCPG has been shown to consistently
block amphetamine-induced locomotor activity while not
producing locomotor effects when injected with saline alone
(Kim & Vezina, 1998b).
The decrease in basal locomotor activity following
MCPG treatment suggests that an interruption of mGlu
activity in developing rats leads to attenuation of
behavioral activity while a more mature system may not
respond similarly. Glutamate stimulates phosphatidyl
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inositol hydrolysis and mobilizes intracellular calcium
through the mediation of mGluRs, in particular mGluRl and
mGluR5, and this activity has been found to be markedly
enhanced in the developing brain relative to the adult
brain (Romano et al., 1996). Intracellular calcium
mobilization stimulates neurotransmitter release, which
regulates cell signaling and motor activity (Grady, Bohm, &
Bunnett, 1997). Results from the present study suggest
that blocking mGlu5 receptors in the developing system
affects mGluR-mediated activity, possibly to the extent of
attenuating motor activity.
Role of mGluR5 in the Expression of Amphetamine- 
induced Behavioral Sensitization
Consistent with previous research, although not
statistically significant, rats pre-exposed to amphetamine
and challenged with amphetamine exhibit patterns of higher
locomotor activity than rats pre-exposed to saline and
challenged with amphetamine. This, to a certain degree,
demonstrates the expression of behavioral sensitization in
which repeated psychostimulant exposure enhances the motor
stimulatory response to a later drug challenge (Pierce &
Kalivas, 1997; Vanderschuren & Kalivas, 2000).
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MCPG pretreatment at the higher dose (25nM)
significantly increased the locomotor response to a
challenge injection of amphetamine (see Figure 2). This
suggests that repeated treatment with MCPG potentiates the
locomotor effects of a single dose of amphetamine when
administered in the absence of the antagonist. Results
from the test day resemble those from the pretreatment
phase in that MCPG failed to consistently block behavioral
sensitization. In addition, to a certain degree, the
effect of MCPG on locomotor activity is independent from
the effects of amphetamine-induced locomotor activity.
Together these results suggest that MCPG does not
consistently affect amphetamine-induced sensitization in
preweanling pups.
Mechanisms of mGluR5-mediated Locomotor 
Activity and Behavioral Sensitization
The role of mGluR5 in modifying behavioral
sensitization has been suggested to involve the actions of
the released dopamine on dopamine Di receptors that are
located on glutamate projections, and when activated, lead
to an increase of extracellular glutamate (Kalivas & Duffy,
1995; Vezina, 1996). Glutamate activates mGluRs,
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initiating long-term intracellular changes such as protein
synthesis, possibly one of the neuroadaptations resulting
in behavioral sensitization (Vezina & Kim, 1999). Previous
studies in adult rats have demonstrated that mGlu5
receptors contribute to the mediating role of the glutamate
system in the development of behavioral sensitization. In
particular, MCPG administration has been found to block
amphetamine-induced locomotion, but have no effect on basal
locomotor activity (Kim & Vezina, 1998).
In the current study of preweanling rats, amphetamine-
induced behavioral sensitization appears to develop
independent of the mGluR5 system, while repeated MCPG
treatment during the induction phase slightly decreased
basal locomotor activity. These behavioral effects of
blocking mGlu5 receptors have been demonstrated in a study
by Zhu et al. (2004) using 2-methyl-6-(phenylethynyl)-
pyridine (MPEP) and 3-[(2-methyl-l,3-thiazol-4-
yl)ethynyl]pyridine (MTEP), both potent, selective mGlu5
receptor antagonists. In their study, MPEP and MTEP
administration both significantly reduced spontaneous
exploratory activity by approximately 78% (Zhu et al.,
2004). This suggests that blocking mGlu5 receptors has
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potentially inhibitory effects on the central nervous
system, as demonstrated in the current study.
The dose-dependent effects of MCPG pretreatment on
locomotor activity following an amphetamine challenge have
been previously demonstrated in adult rats. Different
doses of MCPG, ranging from 0.25nM to 25.0nM, have been
administered to adult rats prior to amphetamine exposure.
Results have shown that while 25.0nM of MCPG completely
blocked amphetamine-induced locomotor activity, 0.25nM of
MCPG potentiated locomotor activity (Kim & Vezina, 1998a;
Kim & Vezina, 1998b). The different behavioral response to
varying doses of MCPG in adult rats suggest the possibility
that blocking mGlu5 receptors has the potential to both
attenuate and potentiate amphetamine-stimulated locomotor
activity.
Considering previous research findings together with
the results from the current study, the functional
interactions between the dopamine and glutamate systems and
the mediating role of mGlu5 receptors appear to involve
complex mechanisms. The enhanced locomotor response to an
amphetamine challenge following MCPG pretreatment was
unexpected and this heightened activity may possibly be the
result of compensatory changes in the dopamine and
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glutamate systems (Grace, 1995; Kim & Vezina, 1998c;
Robelet, Melon, Guillet, Salin, & Kerkerian-Le Goff, 2004).
Repeated treatment with an mGluR5 antagonist, especially at
a high dose, may possibly increase synaptic levels of
glutamate by blocking the regulatory role of mGluRs on
glutamate transmission and release (Kim & Vezina, 1998c).
It has been demonstrated that repeated psychostimulant
administration leading to behavioral sensitization is also
correlated with increased levels of extracellular glutamate
(Pierce, Bell, Duffy, & Kalivas, 1996). Taken together,
the increased locomotor activity produced by an amphetamine
challenge in MCPG pretreated rats, as shown in the present
study, may be mediated by increased levels of synaptic
glutamate.
Conclusion
The current study has demonstrated that behavioral
sensitization can be induced and expressed in preweanling
rats, though this sensitization is not as consistently
blocked by an mGluR5 antagonist as previously shown in
adult studies. Basal locomotor activity was attenuated by
MCPG administration, suggesting an overall inhibitory
effect of blocking mGlu5 receptors. Upon amphetamine
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challenge, repeated MCPG pretreatment resulted in an
enhancement of the locomotor stimulatory response to the
psychostimulant. This may be an indication of the
susceptibility of the developing neuronal system to
modifications in neurotransmission. The immediate action of
an mGluR5 antagonist may be the interruption of dopamine
and glutamate-regulated neuronal functioning, resulting in
attenuated locomotor activity. In contrast, prolonged
exposure to high concentrations of the antagonist may
interact with the neuroadaptations resulting from repeated
amphetamine exposure, possibly leading to stimulatory
effects upon an amphetamine challenge injection. Further
research in developing rats is needed to more fully
understand the mediating role of metabotropic glutamate
receptors in the process of behavioral sensitization, and
to determine the specific neuronal mechanisms responsible
for these locomotor effects.
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